Xoma seeks to sublicense FDC cardiovascular drug for US market
This article was originally published in Scrip
Executive Summary
Xoma has said it is looking to sublicense a fixed-dose combination (FDC) of the ACE-inhibitor perindopril arginine and the calcium channel blocker amlodipine besylate to a third-party that can commercialise the cardiovascular product in the US.